BAM
KRON

Belpointe Asset Management’s Kronos Bio KRON Stock Holding History

Belpointe Asset Management’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-655
Closed -$956 – 2082
2023
Q1 		$956 Buy
655
+62
+10% +$119 ﹤0.01% 3484
2022
Q4 		$961 Buy
+593
New +$1.36K ﹤0.01% 3446

Other funds holding KRON

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PCIG
Partners Capital Investment Group Boston, Massachusetts $2.65B AUM 16.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Belpointe Asset Management's KRON Position: Q2 2023 in Review

Belpointe Asset Management sold out of Kronos Bio (KRON) in Q2 2023, closing a stake of 655 shares — an estimated $956 sold.

Belpointe Asset Management first reported a position in KRON in Q4 2022 and held it in 2 quarters. The position peaked at $961 in Q4 2022. 80 funds tracked by Wall St. Rank hold KRON as of Q2 2023.

  • Belpointe Asset Management reported no remaining Kronos Bio position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 655 Kronos Bio shares in Q2 2023, an estimated $956.
  • Belpointe Asset Management first reported a position in Kronos Bio in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Kronos Bio position peaked at $961 in Q4 2022.
  • 80 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.